Related Experiment Video
Updated: Sep 10, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Coordinated changes in midkine expression and midkine-associated multiomic profile in glioma microenvironment
Mieszko Lachota1,2, Katarzyna Zielniok2, Agata Góźdź3
1Department of Ophthalmology, Children's Memorial Health Institute, Warsaw, Poland.
Abstract:
Midkine (MDK), a multifunctional growth factor, has been implicated in promoting tumor progression, yet its role in glioblastoma (GBM) remains insufficiently characterized. To investigate MDK's function in glioma, we integrated four RNA-Seq datasets into a harmonized cohort of 1,017 adult gliomas, including 256 GBM samples. We complemented this with freshly collected human GBM tissues and matched primary cell cultures to evaluate MDK expression and secretion patterns, further contextualized using single-cell RNA-Seq. Finally, we tested the impact of GBM-derived MDK on macrophage secretome composition to validate our in silico observations. We found that MDK expression increases with tumor grade in IDHwildtype gliomas, accompanied by a shift in isoform proportions favoring the canonical MDK transcript. High MDK expression was associated with poor prognosis specifically in GBM, where the MDKhigh subgroup comprised 75% of cases. MDKhigh GBMs exhibited a distinctive multiomic signature, including elevated chemokine and cytokine expression. Functionally, GBM-derived MDK induced macrophages to secrete multiple cytokines and chemokines, suggesting its role in reshaping the tumor microenvironment. Our findings reveal MDK's previously underappreciated role in GBM aggressiveness and immune modulation, underscoring its potential as a biomarker and actionable therapeutic target for most GBM patients.
Insights
Midkine (MDK) promotes glioblastoma (GBM) aggressiveness and alters the tumor microenvironment by increasing cytokine and chemokine secretion. High MDK expression indicates poor prognosis in GBM, suggesting MDK as a therapeutic target.
Area of Science:
- Neuro-oncology
- Cancer biology
- Immunology
Background:
- Midkine (MDK) is a growth factor linked to tumor progression.
- Its specific role in glioblastoma (GBM) requires further elucidation.
Purpose of the Study:
- To investigate the function and prognostic significance of MDK in glioma, particularly GBM.
- To explore MDK's impact on the GBM tumor microenvironment and macrophage function.
Main Methods:
- Integrated four RNA-Seq datasets (1,017 adult gliomas, 256 GBMs).
- Analyzed fresh GBM tissues, cell cultures, and single-cell RNA-Seq data.
- Assessed MDK's effect on macrophage secretome composition.
Main Results:
- MDK expression correlates with increasing tumor grade in IDHwildtype gliomas.
- High MDK expression (MDKhigh) is linked to poor prognosis in 75% of GBM cases.
- MDKhigh GBMs show elevated chemokine and cytokine expression, and MDK induces cytokine/chemokine secretion from macrophages.
Conclusions:
- MDK plays a significant role in GBM aggressiveness and immune modulation.
- MDK represents a potential biomarker and therapeutic target for the majority of GBM patients.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
PI3K/mTOR/AKT Signaling Pathway

